🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07803588
Recruiting Observational

A Study to Test the AdaptDx Pro Agreement in Rod Intercept Time With the AdaptDx in Healthy Subjects With Normal Vision (FlashBack)

NCT07803588 · tracked via the Priya Life Science USA tracker
Sponsor
AdaptDx, Inc.
Phase
Observational
Started
2026-09-15
Last updated
2026-09-03

Condition(s) studied

Healthy Adult Participants

Investigational drug(s) / intervention(s)

AdaptDx Tabletop vs AdaptDx Pro

AdaptDx Tabletop vs AdaptDx Pro: Two variations of AdaptDx dark adaptation devices.

Study summary

The purpose of this study is to test the AdaptDx Pro agreement in Rod Intercept (RI) time with the AdaptDx tabletop (AdaptDx) in healthy subjects with normal vision.

Eligibility

Sex
ALL
Min age
22 Years
Max age
49 Years
Healthy volunteers
Accepted
Inclusion Criteria: Subjects enrolled in the study will be required to meet all the following criteria for both eyes: 1. Male or female between the ages of 22 and 49 (inclusive) at Visit 1 2. ETDRS BCVA letter score of 85 (Snellen equivalent of 20/20) or better at Visit 1 3. Able to communicate well with the Investigator and able to understand and comply with the requirements of the study 4. Informed of the nature of this study and has provided written informed consent in accordance with institutional, local and national regulatory guidelines Exclusion Criteria: 1. Unable to follow simple instructions, operate a response button or maintain attention for 20 minutes 2. Diagnosis or history of any ocular disease or disorder 3. Serious medical illness that will prevent the subject from performing study activities (including cardiac, hepatic, renal, respiratory, endocrinologic, neurologic, or hematologic disease) or, in the judgement of the Investigator, is likely to require surgical intervention or hospitalization at any point during the study 4. Presence of or history of malignancy within the past year of Visit 1 other than non-melanoma skin or squamous cell cancer or cervical carcinoma in-situ 5. Is non-ambulatory 6. History of drug, alcohol or substance abuse within 3 months prior to Visit 1 7. Has received an investigational drug or treatment with an investigational device within 3 months prior to Visit 1 8. In the opinion of the Investigator, is unlikely to comply with the study protocol

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Retina Consultants San Diego San Diego California Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07803588 on ClinicalTrials.gov ↗ ← All trials in the USA